
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Randomised Trial of Tenectplase Versus Alteplase for Acute Stroke within 4.5h of Onset: The Second Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST-2)
23 Pages Posted: 20 May 2024
More...Abstract
Background: Tenecteplase has potential benefits over alteplase, the standard agent for intravenous thrombolysis in acute ischaemic stroke, because it is administered as a single bolus and might have superior efficacy. ATTEST-2 investigated whether tenecteplase 0.25mg/kg was non-inferior or superior to alteplase 0.9mg/kg within 4.5h of onset.
Methods: We undertook a prospective, multicentre, randomised parallel group open label trial with blinded end-point evaluation in previously independent adults eligible for intravenous thrombolysis <4.5h from symptom onset. Participants were randomised 1:1 to alteplase or tenecteplase. The primary endpoint was the distribution of the day 90 modified Rankin Scale (mRS). Secondary endpoints included excellent (mRS 0-1) and independent (mRS 0-2) recovery, major early neurological improvement, health-related quality of life and whether endovascular thrombectomy was required. We tested the primary outcome for non-inferiority (odds ratio for tenecteplase versus alteplase non-inferiority limit of 0.75), and for superiority if non-inferiority was confirmed. Safety outcomes were mortality, symptomatic intracranial haemorrhage (SICH), radiological intracranial haemorrhage and major extracranial bleeding.
Findings: Between Jan 2017 and May 2023, 1,858 patients were randomised at 39 UK centres. 1,777 patients received study drug; 885 were allocated tenecteplase and 892 alteplase. At randomisation, mean age was 70 years, median NIHSS was 7. Large vessel occlusion was present in 18.7% and 12.4% underwent thrombectomy. Tenecteplase was non-inferior to alteplase for both mRS distribution (odds ratio [95% Confidence Interval] 1.07 [0.90, 1.27], pnoninferiority<0.0001; absolute increase in mRS 0-1, 2.0% [-2.7, 6.8], p=0.002). Tenecteplase was not superior on the primary or any secondary outcome. Death occurred in 68 (7.7%) tenecteplase-treated compared to 75 (8.4%) alteplase-treated patients (OR 0.96, 95% Cis 0.69, 1.33, p=0.79) and SICH in 20 (2.3%) tenecteplase versus 15 (1.7%) alteplase-treated patients (OR 1.37, 95% Cis 0.69, 2.70, p=0.36).
Interpretation: Tenecteplase 0.25mg/kg was non-inferior to 0.9 mg/kg alteplase within 4.5h of symptom onset in acute ischaemic stroke.
Trial Registration: Registered on clinicaltrials.gov (NCT02814409).
Funding: The Stroke Association and British Heart Foundation.
Declaration of Interest: Keith W Muir – Lecture fees, Advisory Board fees from Boehringer Ingelheim; lecture fees from Brainomix, IschemaView; Consultancy fees Abbvie, Biogen, Hyperfine, Lumosa, Woolsey Pharma. Gary A Ford – Personal remuneration for advisory board/steering committee activity from CSLBehring, educational activities from Bayer His employer has received remuneration for consultancy with AstraZeneca. Ian Ford – Research grants to University from The Stroke Association and British Heart Foundation Joanna M Wardlaw – academic research grants but no industry, advisory or speaker fees or stock interests.. Alex McConnachie - Research grants to the University from The Stroke Association and British Heart Foundation. Nicola Greenlaw – Research grants to the University from The Stroke Association and British Heart Foundation. Grant Mair – Personal remuneration for consultancy with Canon Medical Research Europe Ltd. Nikola Sprigg – none. Christopher I. Price – none. Mary Joan MacLeod – Advisory board and educational meeting remuneration from Astra Zeneca. Sofia Dima – none. Marius Venter – none. Liqun Zhang – none. Eoin O’Brien – none. Ranjan Sanyal - none. John Reid – none. Laslo Sztriha – none. Syed Haider - none. Will Whiteley - ESOC guideline for thrombolysis; DMC for TEMPO-2. James Kennedy – none. Richard Perry – none. Sekaran Lakshmanan – none. Annie Chakrabarti – none. Ahamad Hassan – Clinical Advisor to Peninsula Technology Assessment Group, University of Exeter Medical School (External Advisory Group NICE Technology Appraisal of Tenecteplase for treating acute ischaemic stroke, ID6306)- Unpaid. Richard Marigold – none. Senthil Raghunathan – none. Don Sims - none. Mohit Bhandari -Research meeting remuneration for LIBREXIA from Janssen & Bristol Myers Squibb. Ivan Wiggam - none. Khalid Rashed - none. Chris Douglass - none.
Ethical Approval: The trial was approved by Scotland A Research Ethics Committee (ref 16/SS/0137).
Keywords: stroke, treatment, thrombolysis, tenecteplase, alteplase, randomised controlled trial, clinical trial, acute treatment, reperfusion, ischaemic stroke
Suggested Citation: Suggested Citation